Capital Research Global Investors
ELV icon

Capital Research Global Investors’s Elevance Health ELV Stock Holding History

Capital Research Global Investors’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-119,078
Closed -$34.9M – 444
2026
Q1 		$34.9M Sell
119,078
-1,449
-1% -$476K 0.01% 379
2025
Q4 		$42.3M Buy
120,527
+841
+0.7% +$284K 0.01% 357
2025
Q3 		$38.7M Buy
119,686
+793
+0.7% +$247K 0.01% 372
2025
Q2 		$46.2M Buy
118,893
+1,187
+1% +$477K 0.01% 352
2025
Q1 		$51.2M Buy
+117,706
New +$47.3M 0.01% 355

Other funds holding ELV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Capital Research Global Investors's ELV Position: Q2 2026 in Review

Capital Research Global Investors sold out of Elevance Health (ELV) in Q2 2026, closing a stake of 119,078 shares — an estimated $34.9M sold.

Capital Research Global Investors first reported a position in ELV in Q1 2025 and held it in 5 quarters. The position peaked at $51.2M in Q1 2025. 1,303 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Capital Research Global Investors reported no remaining Elevance Health position as of Q2 2026 after selling out during the quarter.
  • Capital Research Global Investors sold 119,078 Elevance Health shares in Q2 2026, an estimated $34.9M.
  • Capital Research Global Investors first reported a position in Elevance Health in Q1 2025 and held it in 5 quarters.
  • Capital Research Global Investors's Elevance Health position peaked at $51.2M in Q1 2025.
  • 1,303 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.